These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7490730)

  • 21. Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
    Chang LL; Ashton WT; Flanagan KL; Chen TB; O'Malley SS; Zingaro GJ; Kivlighn SD; Siegl PK; Lotti VJ; Chang RS
    J Med Chem; 1995 Sep; 38(19):3741-58. PubMed ID: 7562905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
    Bernhart CA; Perreaut PM; Ferrari BP; Muneaux YA; Assens JL; Clément J; Haudricourt F; Muneaux CF; Taillades JE; Vignal MA
    J Med Chem; 1993 Oct; 36(22):3371-80. PubMed ID: 8230127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.
    Cazaubon C; Gougat J; Bousquet F; Guiraudou P; Gayraud R; Lacour C; Roccon A; Galindo G; Barthelemy G; Gautret B
    J Pharmacol Exp Ther; 1993 May; 265(2):826-34. PubMed ID: 8496828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives.
    Bradbury RH; Allott CP; Dennis M; Fisher E; Major JS; Masek BB; Oldham AA; Pearce RJ; Rankine N; Revill JM
    J Med Chem; 1992 Oct; 35(22):4027-38. PubMed ID: 1433210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale for the chemical development of angiotensin II receptor antagonists.
    Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists.
    Edmunds JJ; Klutchko S; Hamby JM; Bunker AM; Connolly CJ; Winters RT; Quin J; Sircar I; Hodges JC; Panek RL
    J Med Chem; 1995 Sep; 38(19):3759-71. PubMed ID: 7562906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.
    Bovy PR; Reitz DB; Collins JT; Chamberlain TS; Olins GM; Corpus VM; McMahon EG; Palomo MA; Koepke JP; Smits GJ
    J Med Chem; 1993 Jan; 36(1):101-10. PubMed ID: 8421274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
    Culman J; von Heyer C; Piepenburg B; Rascher W; Unger T
    Eur J Pharmacol; 1999 Feb; 367(2-3):255-65. PubMed ID: 10079000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist.
    Aiyar N; Baker E; Vickery-Clark L; Ohlstein EH; Gellai M; Fredrickson TA; Brooks DP; Weinstock J; Weidley EF; Edwards RM
    Eur J Pharmacol; 1995 Sep; 283(1-3):63-72. PubMed ID: 7498322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
    Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
    J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydropyrimidine angiotensin II receptor antagonists.
    Atwal KS; Ahmed SZ; Bird JE; Delaney CL; Dickinson KE; Ferrara FN; Hedberg A; Miller AV; Moreland S; O'Reilly BC
    J Med Chem; 1992 Dec; 35(25):4751-63. PubMed ID: 1469703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.
    Cazes M; Provost D; Versigny A; Cloarec A
    Eur J Pharmacol; 1995 Sep; 284(1-2):157-70. PubMed ID: 8549620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computer--based drug design, synthesis and biological evaluation of new pyrimidinone derivatives linked to arylpiperazine and 2'-carbethoxy-biphenylylmethyl moeities as alpha1-adrenoceptor antagonists and angiotensin II AT1 receptor antagonists.
    Ismail MA; Abou El Ella DA; Abouzid KA; Al-Ansary GH
    Pharmazie; 2010 Nov; 65(11):794-800. PubMed ID: 21155384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
    Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
    Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.
    Dhanoa DS; Bagley SW; Chang RS; Lotti VJ; Chen TB; Kivlighn SD; Zingaro GJ; Siegl PK; Patchett AA; Greenlee WJ
    J Med Chem; 1993 Dec; 36(26):4230-8. PubMed ID: 8277505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.
    Keenan RM; Weinstock J; Finkelstein JA; Franz RG; Gaitanopoulos DE; Girard GR; Hill DT; Morgan TM; Samanen JM; Peishoff CE
    J Med Chem; 1993 Jun; 36(13):1880-92. PubMed ID: 8515425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration.
    Paik SH; Chi YH; Lee JH; Han HS; Lee KT
    Biol Pharm Bull; 2017; 40(7):992-1001. PubMed ID: 28674263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonpeptide angiotensin II receptor antagonist recognizes inter-species differences in angiotensin AT1 receptors.
    Kawano K; Fujishima K; Nagura J; Yasuda S; Shinki ; Hachisu M; Konno F
    Eur J Pharmacol; 1998 Sep; 357(1):33-9. PubMed ID: 9788771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.